Background: Tumor-specific mutations form novel immunogenic peptides called neoantigens. Neoantigens can be used as a biomarker predicting patient response to cancer immunotherapy. Although a predicted binding affinity (IC 50 ) between peptide and major histocompatibility complex class I is currently used for neoantigen prediction, large number of false-positives exist.
Introduction
Somatic mutations can cause tumor-specific neopeptide fragments (so-called 'neoantigens'), some of which induce cytotoxic T-cell responses [1] . Importantly, neoantigen prediction can be exploited to identify responders to immune checkpoint inhibitors [2] [3] [4] . Therefore, systematic evaluation of somatic mutations may help advance the promising clinical outcomes of immunotherapies in cancer treatment.
For a somatic mutation to be recognized by cytotoxic T cells, the mutant peptide should be presented by major histocompatibility complex class I (MHC-I) molecules [5] ( Figure 1A ). First, mutant proteins are cut into short peptides by proteasomes and then transported into the endoplasmic reticulum by the transporter associated with antigen processing (TAP). When mutant peptide binds to the MHC-I peptide-binding groove, fully assembled peptide-MHC-I complexes (pMHC-I) are presented at the surface of the plasma membrane. The recognition of a neoantigen by a cytotoxic T cell can activate the T-cell response.
To date, most in silico approaches for neoantigen prediction have been focused on the MHC-I-related presentation of peptides [6, 7] . Because only 0.5% of peptides can bind to MHC-I molecules, prediction of the binding affinity is the most selective step in the recognition of endogenous antigens [8] . Although these tools provide reliable measurements, practical application at the genome-level is limited. First, the prediction of immunogenic neoantigens primarily relies on a single arbitrary cut-off (50 or 500 nM) of a predicted MHC-I binding affinity. Second, isoform-specific gene expression levels of putative neoantigens and other immune signature-related genes are mostly not estimated or considered. Third, the actual analysis requires a series of complex computational processes, which should be handled by bioinformatics experts manually.
Here, we describe a new machine-learning-based method to address the noted problems above and its implementation. The program, called Neopepsee, harnesses gene-and protein-level information and a novel feature to achieve maximum accuracy: improved performance was validated in a cross validation and an independent in vivo study.
Materials and methods

Collection of potential immunogenicity features
To build a classifier that maximizes the usage of information, we initially collected 13 potential features that have been previously reported or hypothesized for predicting immunogenicity. The 13 potential features were divided into three groups based on their representative biologic meanings: (A) MHC-I binding and presentation, (B) amino-acid characteristics, and (C) complex scores. For (A), seven features have been collected and scored, including 'IC 50 ' and 'percentile rank'-based predictive values for MHC-I binding affinity, NetCTLpan [9] based scores for 'MHC-I binding, protein cleavage, TAP transport efficiency' and their 'combined score'. A score for 'T-cell recognition' of the pMHC-I molecule [10] was also considered. For (B), four features have been collected including 'hydrophobicity' of amino acids at TCR contact residues [11, 12] , 'polarity and charged value' of amino acids at position 2, 3, 5, and 6 [12] , 'molecular size' [13] , and 'entropy of peptides' [14] . In addition, two complex scores for 'differential agretopicity index (DAI)' [15] and 'amino acid pairwise contact potentials (AAPPs)' [16] were further considered. More detailed evidences and rationales for collected features are provided in the supplementary data, available at Annals of Oncology online.
In addition to the 13 feature, we defined a new score, 'a sequence similarity to known epitopes', in light of a previous hypothesis between the similarity and immunogenicity [17, 18] . As the fundamental objective of the immune response is to distinguish non-self peptides from self, we assumed that these mutations could be prioritized by developing a proper measure. The 14 features are enlisted in the supplementary Table S1 , available at Annals of Oncology online.
Construction of control positive and negative dataset
To construct the positive dataset (supplementary Table S2 , available at Annals of Oncology online), we initially collected 1113 epitopes and their corresponding HLA alleles that were reported to exhibit positive T-cell response in humans [10] . To find epitopes that can be generated by hypothetical somatic mutations in human genome, we compared the sequences of the 1113 epitopes with those of the 20 198 reviewed SwissProt human proteins [19] to only retain 311 epitopes whose sequences are differed from the best-match by up to 2 amino acids; the best-match protein was further used as a corresponding wild-type.
For negative dataset, we initially collected 22 245 variants from common (minor allele frequency [MAF] !0.05) non-synonymous single nucleotide polymorphisms (SNPs) from dbSNP v.141 with the assumption that widespread peptide variants would not lead to an immunogenic response. The HLA allele for negative dataset was randomly selected from HLA alleles of the positive set. To maintain the naturally occurring balance between positive and negative neopeptides (ratio 1-48) [20] , we randomly selected 14 633 out of the 22 245 mutant peptides to finalize the negative dataset.
Feature selection procedure
To achieve better classification accuracy and to reduce the risk of overfitting, we conducted feature selection from the 14 scores. Cleavage and TAP of the 14 scores were initially excluded due to the lack of consistency reported by a previous study [9] . For 12 remaining features, two major criteria were applied for selection: (1) informativeness of the feature in classification and (2) inter-dependency between features that causes redundancy.
To measure informativeness, three different analyses were used: correlation-based feature selection [21] , information gain-based feature selection [22] , and classification power achieved by a single feature. The single feature based classification power enables the prediction of the discriminative power of a feature in a trained machine learning classifier, which is represented by area under a curve (AUC) and area under a precision-recall curve (AUPRC). The final informativeness is measured by a merged score (supplementary Figure S1A and Table S3 , available at Annals of Oncology online). Pearson and Spearman correlation were used to remove overlapping effects between inner individual features. If correlation between two features was higher than 0.8 in both methods, one was excluded. Finally, nine immunogenicity features: IC 50 , rank, combined score, immunogenicity score, hydrophobicity, polarity&charged score, DAI, AAPPs, and similarity were utilized to construct the machinelearning classifiers (see details in the supplementary data and Figures S2-S6, available at Annals of Oncology online).
Machine-learning-based classification for immunogenicity prediction
On the basis of the selected immunogenicity features, the machine-learning-based classifiers were constructed for four learning models: Gaussian naïve Bayes (GNB), locally weighted naïve Bayes (LNB), random forest (RF), and support vector machine (SVM).
To evaluate classifiers, we used 500 iterations of 10-fold crossvalidation on the constructed dataset and measured the performance. In the training step, calculated immunogenicity features of the dataset were fed into four classifiers. Then we validated the performance of four trained classifiers and conventional methods on the independent dataset.
Results
Overall workflow of Neopepsee
The overall workflow is shown in Figure 1B . RNA-seq data and a list of somatic mutations are required for analysis. The HLA allele can be supplied as an optional input; otherwise, it can be inferred computationally from the RNA-seq data. For each nonsynonymous somatic mutation, affected peptides are calculated Figure 1 . MHC-I antigen presentation pathway and corresponding Neopepsee procedure. (A) The mutant peptide (mutation sequence represented in red) from a tumor-specific antigen can be present in the plasma membrane of the major histocompatibility complex (MHC)-I molecule as the result of a series of reactions. First, tumor-specific antigens are degraded by the proteasome (Process 1). Then, the resulting peptides are transported via transporters associated with antigen presentation (TAP) into the endoplasmic reticulum (ER) lumen. The neopeptide binds to the binding-groove of MHC-I molecules (Process 2). Peptide-MHC class I complexes (pMHC-I) are then transported via the endoplasmic reticulum (ER)-Golgi pathway to the plasma membrane for antigen presentation to activate CD8þ T cells. MHC-I, major histocompatibility complex I; b2m, b2-microglobulin; TCR, T-cell receptor. (B) Overall Neopepsee workflow. Somatic mutations and gene expressions of a given tumor tissue are assessed for neoantigen prediction. In total, 9 immunogenicity features are calculated for each mutant neopeptide and fed into a classifier. Green boxes denote unique modules in Neopepsee.
and prepared for further analysis (see details in the supplementary data, available at Annals of Oncology online). Neopepsee classifies the potential neoantigens into three categories (high, medium, and low) with respect to the predicted immunogenicity, and reports the results along with 87 immunogenicity-related values, including conventional predictions (supplementary Table  S4 , available at Annals of Oncology online), expression levels of neopeptides and immune regulatory genes (e.g. PD1 and PD-L1). The overall accuracy at the specific threshold was measured. Conventional thresholds for immunogenicity prediction used 500 nM for IC 50 and 2.49 for percentile rank, respectively [2, 18, 23] . We divided the candidate neoantigens into three classes regarding the output membership probability of the trained classifiers: high (the most precise), medium (the most sensitive) and low. The lowest membership probability, which qualifies sensitivity level of 0.95 to exclude outliers, is set as threshold for medium class. The threshold for high class is the highest membership probability at which specificity is above 0.95. All other peptides were classified as the low class. As expected, high class had greatly increased precision and specificity with a slight loss of sensitivity in the test step, whereas the medium class was optimized for increased sensitivity.
Evaluation of neoantigen prediction in Neopepsee
In terms of AUC and AUPRC, the RF and SVM classifiers showed the best performance. However, the low thresholds at the membership probability in the medium class implied the perceptual tendency to call a smaller number of answers to prioritize specificity in both models. The tendency led to a drastic drop of precision at obtaining higher recall ( Figure 2B ). Therefore, LNB was finally selected as a classification model based on performance robustness.
Tests on independent experimental data
Neopepsee was tested on independent datasets from recent studies that reported experimentally confirmed immunogenic and non-immunogenic peptides in melanoma [23] and chronic lymphocytic leukemia [24] patients (Figure 3 ). Both studies validated the induced T-cell responses experimentally using a MHC dextramer assay to evaluate vaccine-induced T-cell responses [23] or an IFN-c ELISPOT assay to measure spontaneous T-cell responses [24] . From both studies, 1093 peptides were obtained, 65 of which were validated (12 immunogenic and 53 non-immunogenic). The number of total calls and true/ false positives was assessed in the medium and high classes of Neopepsee and further compared with the conventional criteria ( Figure 3A and supplementary Table S5 , available at Annals of Oncology online).
Regarding sensitivity, IC 50 and the medium class called all 12 answers: note that the perfect sensitivity for IC 50 is expected, because the peptides for validation were initially selected by IC 50 . Classification using percentile rank and the high class missed one and two answers, respectively. However, the high class only Figure 2 . Performance evaluation for Neopepsee. (A) ROC curves of four predictive models (Gaussian naïve Bayes, locally weighted naïve Bayes, random forest, and support vector machine) and two conventional methods (IC50 and percentile rank). All four predictive models outperformed the conventional methods. (B) pROC curves of the same six models. All four predictive models show better performance than the conventional methods. AUPRC is maximized in the RF model; however, an acute drop in the high recall area is observed; LNB shows the best performance when the recall was 1. GNB, Gaussian naïve Bayes; LNB, locally weighted naïve Bayes; RF, random forest; SVM, support vector machine; RANK, percentile rank. For more accurate comparison of discriminative power, the distributions of scores were plotted for immunogenic and nonimmunogenic peptide groups ( Figure 3B ). The P-value of discriminative power was calculated by Wilcoxon rank sum test. The results showed a tighter clustering of immunogenic peptides, with a better separation from non-immunogenic peptides (P-value, 6.84eÀ05). While the majority of non-immunogenic peptides are assigned with low probabilistic scores (<0.5), separation of false negatives with very high scores ($1.0) would be the key to achieving better separation, which we expect with continued accumulation of validated data for training.
Application to The Cancer Genome Atlas stomach adenocarcinoma (TCGA-STAD) dataset
We applied Neopepsee to a large cancer genome cohort. A total of 224 samples were analyzed, and 3760 putative neoantigens were identified. The median of somatic single-nucleotide variants (SNV) was 49 and the median of putative neoantigens was 7 ( Figure 4A ). The number of somatic SNVs largely differed according to microsatellite instability (MSI) status (median of 452 in MSI-high, 56 in MSI-low, and 40 in microsatellite stable [MSS] tumors; Figure 4B ). The number of neoantigens in MSIhigh tumors (median, 68) was higher than that of MSI-low (median, 10) or MSS tumors (median, 5). Interestingly, tumors with neoantigens exhibited better prognosis compared with tumors without neoantigens (29.1 versus 14.1 months without neoantigens; log-rank P ¼ 0.024; Figure 4C ). However, MSI status was not significantly associated with overall survival (29.4 versus 26.7 months with MSS; log-rank P ¼ 0.616; Figure 4D ). Recently, Rooney et al. calculated immune cytolytic activity scores as indicators of CD8þ T-cell activation and showed neoantigens to be likely to induce cytolytic activity [25] . In the cox-regression analysis, the absence of neoantigens and advanced tumor stage (III and IV) were identified as independent prognostic factors for overall survival ( Figure 4E ). The positivity of neoantigen was associated with improved overall survival in both univariate (hazard ratio, 3.1; P ¼ 0.022) and multivariate analysis (hazard ratio, 2.2; P ¼ 0.040). Our data suggest that increased neoantigen loads by microsatellite instability, not MSI status itself, may be a favorable prognostic factor. Of 3760 neoantigens, only 16 (0.42%) were found in more than one tumor sample (supplementary Table S6 , available at Annals of Oncology online). We compared identified neoantigens with known immune epitopes. In addition to known Helicobacter pylori epitopes (n ¼ 7, Supplementary Figure S7A , available at Annals of Oncology online), we identified a total of 1867 known immune epitopes (supplementary Table S7 , available at Annals of Oncology online). Most immune epitopes are derived from Mycobacterium tuberculosis (24%), Trypanosoma cruzi (19%), Vaccinia virus (6%), Human herpes virus (4%), and, Hepatitis C virus (2%), many of these bacteria/viruses can induce chronic inflammation, one of critical mediators of tumor development including gastric cancer (supplementary Figure S7B , available at Annals of Oncology online).
Discussion
Owing to the great diversity, multi-step biochemical processes, and the stochastic nature of T-cell immune response, accurate prediction of neoantigen has been one of the most challenging problems in the immunoinformatics field. As we assumed, a single value associated with a part of the whole process can hardly provide sufficient information to resolve the complexity. In this context, systematic integration of multiple features into a unified workflow is urgently needed to increase the accuracy and to provide a sustainable framework that exploits the growing information. Notably, a recent study to predict MHC-I-binding peptides based on mass spectrometry shed light on identifying binding motifs and antigen processing rules [26] . We expect that such advances will reinforce Neopepsee through a continuous retraining of the machine learning classifier with updated datasets and feature selection. One of the ultimate goals of neoantigen prediction software is to classify patients who will benefit from immunotherapy, or to design a personalized cancer vaccine. Recent studies showed that higher mutational burden was correlated with better antitumor activity of CTLA4 or PD-1 blockade [3, 4, 18] . Although the number of neopeptides generated by somatic mutation seemed to be important for predicting antitumor activity of immunotherapy, the criteria to identify neopeptides and the correlation were inconsistent across studies [3, 18] . Future studies identifying optimized selection criteria for neopeptides and further correlative analysis are warranted. Since most neoantigenic peptides are not identical between tumors [4] , cancer vaccines targeting neopeptides may not be a 'universal' solution that provides broad coverage to cancer patients. Nevertheless, Neopepsee will enable the efficient analysis of a personal somatic mutation profile and identification of potential neopeptides for personalized vaccination.
In summary, Neopepsee can be applied not only to identify putative neoantigens, but also to compare neoantigens with known immune epitopes. The analysis results can be used for subsequent prognostic/predictive biomarker discovery or to design antigens for cancer vaccines. 
